Grifols (GRFS) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $5.74B, a trailing price-to-earnings ratio of 13.2 and a free-cash-flow yield of 12.2%. Over the most recent reported fiscal year, revenue grew 4.3% and free cash flow per share grew 17.4%. Nama's AI scorecard rates it Buy, 5.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Buy · 5.8/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Trailing · -10.3% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-36.8%
How far the last close sits under the highest price of the past five years.
Market cap
$5.74B
Trailing P/E
13.2
Price / book
0.9
Price / sales
0.7
FCF yield
12.2%
Dividend yield
1.3%
Gross margin
37.0%
Operating margin
16.2%
Net margin
6.0%
Revenue growth (YoY)
+4.3%
Revenue growth (3-yr annual)
+7.5%
EPS growth (YoY)
—
FCF/share growth (YoY)
+17.4%
Beta
1.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers General
GRFS earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.39).
Beat the EPS estimate in 0 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Jul 27, 2026
$0.17
$0.28
-39.3%
$2.10B
Q2 2025
Jul 28, 2025
$0.22
$0.28
-21.4%
$2.12B
Q2 2024
Jul 30, 2024
$0.15
$0.23
-34.8%
—
Q2 2023
Jul 27, 2023
$0.10
$0.15
-33.3%
—
GRFS analyst price target
Median target $10.37 from 2 analysts, ranging $9.00 – $11.73.
Nama's AI scorecard currently rates Grifols Buy (5.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GRFS's P/E ratio?
Grifols trades at a trailing price-to-earnings ratio of 13.2.
When does GRFS report earnings?
Grifols's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.39.
What is the GRFS price target?
The median analyst price target from 2 analysts is $10.37, with a range of $9.00 – $11.73.
Is GRFS Shariah compliant?
Nama's AAOIFI-style screen reads Grifols as Not Shariah Compliant. At least one of the three ratios or the industry test failed.